{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zane LK"],"funding":["National Cancer Institute (NCI)","Intramural NIH HHS","National Cancer Institute","NCI NIH HHS"],"pagination":["3512-3525"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12284871"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(16)"],"pubmed_abstract":["<h4>Purpose</h4>NCI selected a network of Clinical Laboratory Improvement Amendments-certified laboratories performing routine next-generation sequencing (NGS) tumor testing to identify patients for the NCI Molecular Analysis for Therapy Choice (NCI-MATCH) trial. This large network provided a unique opportunity to compare variant detection and reporting between a wide range of testing platforms.<h4>Experimental design</h4>Twenty-eight NGS assays from 26 laboratories within the NCI-MATCH Network, including the NCI-MATCH central laboratory (CL) and 11 commercial and 14 academic designated laboratories (DL), were used for this study. DNA from eight cell lines and two clinical samples were sequenced. Pairwise comparisons in variant detection and reporting between each DL and CL were performed "],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial."],"pmcid":["PMC12284871"],"funding_grant_id":["U10CA180820","HHSN261201500003I","UG1 CA233180","U10 CA180820","UG1CA233180","HHSN261201500003C","Z99 CA999999"],"pubmed_authors":["Chang TC","Solomon JP","Karlovich C","Sims DJ","Poorman K","Tomlins SA","for NCI-MATCH Designated Laboratories","Lopategui J","Telatar M","Zane LK","Benson K","LoBello JR","Livingston RJ","Funari VA","Vail E","Sorrells S","Baschkopf GX","Yang G","Freitas TAK","Harris LN","Hamilton SR","Tsongalis GJ","Xu D","Meyers B","Kolhe R","Li P","Baltay M","Conley BA","Pavlick DC","Wen JD","Frampton GM","Li L","Mansukhani MM","Williams PM","Trent JM","Lindeman NI","O'Dwyer PJ","Zeng J","NCI-MATCH Designated Laboratories","Aisner DL","Conroy JM","White K","Brown NA","Jiang L","Chandra PK","for NCI-COMPASS Team","Tandon B","Walther Z","Flaherty KT","Iafrate AJ","Sholl LM","Hovelson DH","Harrington R","Weiss L","Raffeld M","Sklar J","Xi L","Yee LM","Beaubier N","Tell R","Chen AP","Kelly K","Harper K","Afkhami M","Hsiao SJ","Song W","Stehr H","Miller VA","Champion KJ","Segal JP","Adams E","Fesko YA","King D","McShane LM","Konnick EQ","Zhang W","Aldape KD","Swat W","Ma C","Davies KD","Patton DR","Szelinger S","Tricoli JV","Prescott JL","Uvalic J"],"additional_accession":[]},"is_claimable":false,"name":"A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial.","description":"<h4>Purpose</h4>NCI selected a network of Clinical Laboratory Improvement Amendments-certified laboratories performing routine next-generation sequencing (NGS) tumor testing to identify patients for the NCI Molecular Analysis for Therapy Choice (NCI-MATCH) trial. This large network provided a unique opportunity to compare variant detection and reporting between a wide range of testing platforms.<h4>Experimental design</h4>Twenty-eight NGS assays from 26 laboratories within the NCI-MATCH Network, including the NCI-MATCH central laboratory (CL) and 11 commercial and 14 academic designated laboratories (DL), were used for this study. DNA from eight cell lines and two clinical samples were sequenced. Pairwise comparisons in variant detection and reporting between each DL and CL were performed ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-07-15T18:08:02.028Z","creation":"2026-07-08T03:08:47.042Z"},"accession":"S-EPMC12284871","cross_references":{"pubmed":["40465838"],"doi":["10.1158/1078-0432.CCR-24-2188","10.1158/1078-0432.ccr-24-2188"]}}